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Abstract. Prostratin, a phorbol ester natural plant compound, 
has been demonstrated to exert an anti-retroviral effect 
through activation of latent cluster of differentiation (CD)4+T 
lymphocytes and inhibition of viral entry into the cell through 
downregulation of chemokine receptor type 4 (CXCR4) 
expression. However, the potential effect of prostratin on 
cancer is yet to be defined. As CXCR4 is well known to induce 
cancer migration, it was hypothesized that prostratin induces 
an anti-cancer effect through inhibition of CXCR4 expression. 
The authors previously demonstrated that high stimulating 
conditions (sub-minimal IL-17, 0.1 ng/ml, synergized with 
high salt, Δ0.05 M NaCl) promote breast cancer cell prolif-
eration and CXCR4 expression through upregulation of 
salt-inducible kinase (SIK)-3. The present study demonstrated 
that prostratin selectively exerted increased cytotoxicity (IC50 
of 7 µM) when breast cancer cells were cultured in high 
stimulating conditions, compared with regular basal culture 
conditions (IC50 of 35 µM). Furthermore, the cytotoxic poten-
tial of prostratin was increased seven-fold in the four breast 
cancer cell lines (MCF‑7, MDA‑MB‑231, BT‑20 and AU‑565) 
compared with the non‑malignant MCF10A breast epithelial 
cell line. This suggested that prostratin specifically targets 
cancer cells over normal cells. Mechanistic studies revealed 
that prostratin inhibited CXCR4 expression in breast cancer 
cells through downregulation of SIK3 expression. Overall, 
the data suggest that prostratin is a novel drug target for the 
pro-oncogenic factor SIK3. These studies could form a basis 
for further research to evaluate the anticancer effect of pros-
tratin in a combinatorial chemotherapeutic regimen.
Introduction
Chronic inflammation is a well‑established hallmark of cancer 
proliferation (1). The cellular stress caused by inflammation 
induces release of cytokine and chemokine factors which 
induce tumor progression and metastasis (2). Several agents 
have been suggested to induce chronic inflammation (3). 
Recent evidence from our lab have demonstrated that breast 
cancer cells cultured under high salt conditions (Δ0.05 M 
NaCl, 50% above basal culture conditions) were able to upreg-
ulate reactive nitrogen species (4,5). Importantly, sodium-MRI 
studies in breast cancer patients have demonstrated an 
increased sodium content, of up to 63% above the surrounding 
soft tissue, in the breast tumors (6,7). These support a notion 
that high salt exerts an effector role on tumor progression, 
either working individually or synergistically to enhance an 
inflammatory tumor microenvironment. Phospho‑proteomic 
based studies from our laboratory have demonstrated that high 
salt (Δ0.05 M) synergized with sub-minimal stimulation of 
IL-17 (0.1 ng/ml) induced upregulation of SIK-3, salt induc-
ible kinase‑3, a serine‑specific protein kinase in breast cancer 
cells (8). Mechanistic studies have demonstrated that SIK3 
played a crucial role in induction of G1/S-phase release of cell 
cycle, along with enhanced expression of metastasis specific 
chemokine CXCR4 in breast cancer cells.  Histone deacety-
lase (HDAC4) is a well‑documented downstream target of 
SIK3 (9). The phosophorylation of HDAC4 is known to induce 
cell proliferation and malignancy. SIK3 induced phosphoryla-
tion of HDAC4. Further, equimolar treatment with mannitol or 
sucrose did not exert similar pro-cancer effect, thus strongly 
suggesting that high sodium chloride specifically induces a 
pro-cancer effect (8).
Natural plant product prostratin (12-deoxyphorbol 
13-acetate) is widely studied for it's activation of latent 
T‑cells infected with HIV. Prostratin is identified as a phar-
macologically active ingredient in the Samoan medicinal 
plant Homolanthus nutans (10). Molecular studies have 
demonstrated that prostratin exerts its anti-HIV effect through 
activation of protein kinase C (11). Importantly, prostratin 
is shown to induce downregulation of chemokine receptor 
CXCR4 in CD4+T lymphocytes there by preventing the entry 
of HIV-1 virus into lymphocytes (12).
The C-X-C chemokine receptor type 4 (CXCR4), belongs 
to the superfamily of the heterotrimeric G protein-coupled 
receptors and is expressed on the cell surface of various types 
of metastatic breast cancer cells. It is important to note that the 
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role of CXCR4 in cell proliferation and metastasis was obtained 
from the elegant studies performed by Dewan et al (13), when 
less invasive MCF-7 breast cancer lines with low expression 
of CXCR4 formed much smaller tumor mass the SCID-mice 
compared to those larger tumor size the highly invasive 
MDA‑MB‑231 cell line with high expression of CXCR4. This 
is further corroborated with the studies by Lapteva et al (14), 
where in, siRNA based knock‑down of CXCR4 in breast cancer 
cells tumors cells decrease the tumor growth and size in the 
murine breast cancer models. Taken together, as prostratin has 
shown to mediate CXCR4 downregulation in HIV infected 
cells and CXCR4 is important for cancer proliferation, in our 
current communication, we studied the anti-cancer effect of 
prostratin through modulation of CXCR4 expression on cancer 
cells.
Materials and methods
Cell cultures and plasmids. Five breast tissue related cell lines 
were used in our studies, of these, four breast cancer cells 
(MCF7, MDA‑MB‑231, BT20, AU565) and one normalized 
breast epithelial cell line (MCF10A) were utilized and obtained 
from the American Type Culture Collection (ATCC, Manassas, 
VA, USA). The cells were cultured in cell basal essential media 
(RPMI‑1640 media; Thermo Fisher Scientific, Inc., Waltham, 
MA, USA) along with the media supplements such as fetal 
bovine serum, penicillin/streptomycin, fungizone, HEPES and 
glutamine, as recommended by the manufacturer and as previ-
ously described (4,15). Cell lines were frozen in liquid vapor 
nitrogen at ‑130˚C until use. Upon thawing, cells were main-
tained in 5% CO2 incubator in sterile essential media at 37˚C. 
For salt and interleukin-17 treatment conditions, cell culture 
media was supplemented with 0.05 M NaCl (Sigma‑Aldrich; 
Merck KGaA, Darmstadt, Germany) and 0.1 ng/ml IL‑17 
(Thermo Fisher Scientific, Inc.). We have previously performed 
a dose-response for salt (0-0.1 M NaCl) and IL-17 (0-1,000 ng/
ml) and found-out that 0.05 M NaCl provided highest cell 
proliferation (4,5) and 0.1 ng/ml of IL-17 induced sub-effective 
inflammatory cytokine response (4,16). All chemicals unless 
mentioned were obtained either from Sigma‑Aldrich; Merck 
KGaA (Darmstadt, Germany) or Thermo Fisher Scientific, Inc. 
For siRNA knock down of SIK3 we have used the following 
two siRNA sequences: SIK3‑siRNA‑1: 5'‑GUG CAG AGU GUU 
GGA GUC C‑3'; scramble SIK3‑siRNA‑1: 5'‑UGG AGG CGA 
GUC AGU UUG C‑3'.
Western blot/immunoprecipitation. Total proteins were 
extracted from cells with lysis buffer for western blot analysis 
as previously described (17,18). Total proteins were separated 
on a 4-12% sodium dodecyl sulfate-polyacrylamide gradient gel 
and transferred onto a nitrocellulose membrane. The membranes 
were blocked overnight at 4˚C in Tris‑buffered saline with 0.05% 
Tween 20 (5% nonfat milk in 10 mM Tris-HCl-100 mM NaCl-0. 
1% Tween 20, pH 7.4). The membranes were incubated first with 
Abs specific for total and phosphorylated forms at room temper-
ature with primary Abs diluted 1 in 1,000 in blocking buffer for 
2 h, and then with a horseradish peroxide-conjugated secondary 
IgG mAb diluted 1 in 5,000 for 1 h. All primary and secondary 
Abs were obtained from Santa Cruz Biotechnology, Inc., (Dallas, 
TX, USA). All primary and secondary antibodies for western 
blot and immunoprecipitation were obtained from either Abcam 
(Cambridge, MA, USA) or Santa Cruz Biotechnology, Inc. The 
following specific primary antibodies to SIK3 (ab211424; Abcam) 
GADPH (sc‑47724), Actin (sc‑8432), HDAC4 (sc‑46672; all 
from Santa Cruz Biotechnology, Inc.), pHDAC4‑S632 (ab39408; 
Abcam). The membrane was developed using the chemilumines-
cence kit (EMD Millipore, Billerica, MA, USA) and analyzed 
on using Universal Hood II by Bio‑Rad Laboratories, Inc., 
(Hercules, CA, USA). Morphometric analysis was done using 
the software provided by the company.
For SIK3 immunoprecipitation, the cultured cells were 
washed with cold PBS, and lysed for 30 min on ice with 0.5 ml 
of lysis buffer as previously mentioned (16,19). To the lysis 
buffer 0.5 ml of dilution buffer was added and centrifuged 
at 17,000 x g for 30 min. The supernatant was transferred 
and 1 µg normal chicken IgY (ab97135; Abcam) or chicken 
anti‑SIK3 were added. After overnight incubation at 4˚C, 30 µl 
carbolink beads (Pierce, Thermo Fisher Scientific, Inc.) were 
added to lysates and incubated for 2 h for chicken antibody 
immunoprecipitation as per manufacturer's protocol. Beads 
were washed with 700 µl of wash ice cold buffer four times, 
3 min each time followed by centrifugation at 1,800 x g for 
3 min at 4˚C. Beads were then washed with cold PBS and bound 
proteins were eluted by boiling with 30 µl of 2X SDS buffer 
for 10 min. Proteins were subjected to SDS‑PAGE (4‑12% gel) 
and immunoblotting. Phosphorylation of SIK3 were detected 
with a mouse monoclonal phospho‑serine antibody (sc‑81514; 
Santa Cruz Biotechnology, Inc.).
Reverse transcription‑quantitative polymerase chain reac‑
tion (RT‑qPCR). Expression profiles of genes at mRNA level 
in the breast cancer cell lines were analyzed using the TaqMan 
FAM‑labeled RT‑PCR primers for SIK3 (Hs00228549_m1), 
GADPH (Hs402869), and Actin (Hs4333762T), obtained 
from Applied Biosystems; Thermo Fisher Scientific, Inc. 
as per the manufacturer's recommendation. Briefly, total 
RNA was extracted from 106 cells using TRIzol reagent 
(Sigma‑Aldrich; Merck KGaA) and analyzed as mentioned 
previously (20-22). RNA samples were quantified by absor-
bance at 260 nm. The RNA was reverse‑transcribed and 
RT‑PCR (real time PCR) was performed in a final reaction 
volume of 20 µl using CFX96 (Bio‑Rad Laboratories, Inc.). 
Each sample was analyzed in triplicate. Cycling conditions 
consisted of an initial denaturation of 95˚C for 15 min, 
followed by 40 cycles of 95˚C for 30 sec, followed by 61˚C 
for 1 min.
Cell proliferation assay. Cell viability was measured by 
trypan blue dye exclusion (Sigma‑Aldrich; Merck KGaA) and 
MTT assay (Thermo Fisher Scientific, Inc.) as previously 
described (4). Briefly, the viability of breast cancer cells was 
assessed by measuring mitochondrial activity using MTT 
(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide) 
assay. For various treatment conditions the cancer cells were 
plated in 96 well plate for 48‑72 h, the cells were incubated with 
5 mg/ml MTT in PBS for 2 h, latter lysed with manufacturer 
provided reagents. Detection at 570 nm was performed using 
EMax Plus spectrophotometer and data analysis was carried 
out using software provided by the manufacturer (Molecular 
Devices, LLC, Sunnyvale, CA, USA). Viability was calculated 
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as percentage compared to untreated cells. Drug dose-reponse 
parameters were obtained using the following equation:
y=100 ‑ [A*x/(K + x)]
where, y is cell viability (%); x is prostratin concentration (µM); 
A is defined as the maximum cell viability following highest 
drug treatment, this data will be reported as maximal prostratin 
cytoxicity (Cmax), as represented as (100‑A); K is defined as the 
concentration of prostratin at which there is 50% of Cmax loss 
of cell viability and is reported as IC50. While Cmax and IC50 
are obtained by best curve fit (with R‑square value >0.95), the 
highest drug treatment within the limitation of our experimental 
data collection is shown at approximately three fold concentra-
tion above IC50. The best curve fit was analyzed using Microcal 
Origin v7.0 (Microcal Software, Westborough, MA, USA).
HDAC4 assay kit. The HDAC4 activity analysis (Epigentek, 
Farmingdale, NY, USA) was performed on the nuclear frag-
ments of the cell lysates under various assay conditions as per 
manufacturer's instructions. Calorimetry detection at 450 nm 
was performed using EMax Plus spectrophotometer and 
data analysis was carried out using software provided by the 
manufacturer (Molecular Devices, LLC). The data analysis 
was performed based on a standard curve obtained using the 
positive controls provided by the manufacturer as previously 
described.
CXCR4 membrane expression assay. CXCR4 expression was 
analyzed by flow cytometry as previously described (23). Briefly, 
the CXCR4 protein was labeled by mouse anti-CXCR4 primary 
antibody (Santa Cruz Biotechnology, Inc.) in 1:20 dilution to a 
200 µl final volume of cells (1x105 cells/ml). Antibodies used 
for flow cytometry included anti‑mouse‑FITC (BD Biosciences, 
San Jose, CA, USA), and the samples were latter analyzed using 
a FACS Calibur/LSRII flow cytometer (BD Biosciences). Data 
were analyzed using BD FACSDiva software. Gates were set 
according to isotype controls.
Statistical analysis. All data were presented as mean 
values ± SEM from four independent experiments. Student 
t-test performed for statistical analysis. P<0.05 was considered 
to indicate a statistically significant difference. All data 
analysis were performed using Origin 6 software (Origin 
Labs, Northampton, MA, USA) or SPSS software v21 (IBM 
Corp., Armonk, NY, USA).
Results
Enhanced cytotoxic effect of prostratin on breast cancer cells 
in the presence of high salt environment. To study the effect 
on prostratin on breast cancer cells in the presence on high 
salt environment, we first determined the drug's cytotoxicity. 
We have previously demonstrated that high salt (Δ0.05 M 
NaCl) synergized with subminimal IL-17 (0.1 pg/ml) (16) to 
induce a 24% enhanced cell proliferation (4,5,8,22), which 
will be referred to as stimulating conditions in our current 
communication. Importantly, Na-MRI based human studies 
have revealed that breast tumors accumulate high salt for 
yet unknown reasons (6,7). As shown in Fig. 1A, prostratin 
induced inhibitory effect on cell proliferation in MCF-7 breast 
cancer cells, however, this cytotoxic effect was higher when 
cells were culture in high salt culture environment. Further 
data analysis has revealed that (Fig. 1B) the IC50 of prostratin 
on MCF-7 cells under basal culture conditions was 37.4±8.7 µg, 
while under high salt stimulating conditions the IC50 was 
determined to be 7.3±2.9 µg. This suggests that natural plant 
product prostratin has more efficient anti‑tumor activity under 
tumor microenvironment conditions similar to real human 
cancer patients.  We have further verified this cytotoxic effect 
on other breast related cell lines. In our current study we have 
used four breast cancer cell lines namely, MCF-7 (ER/PR 
double positive), MDA‑MB‑231 (triple negative), BT‑20 (Triple 
negative), AU‑565 (Her2 positive); and one non‑malignant 
breast epithelial cell line, MCF‑10A. As shown in Fig. 1B, 
prostratin has upto seven fold higher cytotoxicity (as deter-
mined by low IC50) on breast cancer cells over non-malignant 
cells. Of the four breast cancer cell lines, although statistically 
insignificant, prostratin seemed to exert higher effect (as deter-
mined by Cmax) on the two highly invasive (metastatic) cell 
lines, MDA‑MD‑231 and BT‑20 (Fig. 1B). These data strongly 
suggest that prostratin can selectively exert it's effect on breast 
tumor with minimal effect on normal breast epithelium.
Prostratin inhibits SIK3 expression and phosphorylation. As 
we have previously demonstrated that SIK3 plays a critical role 
in mediating high salt induced cancer cell proliferation (8). In 
our current study, we studied the potential cytotoxic effect of 
Figure 1. Prostratin induces cytotoxicity in breast cancer cells. (A) Dose titration of prostratin (0 to 200 µM) on MCF‑7 cells; (filled squares) represent cells 
cultured under basal conditions; (open circles) represent cells cultured under high salt stimulating conditions (Δ0.05 M NaCl+0.1 ng/ml IL‑17). (B) Dose titra-
tion was performed on the five breast cell lines, of which four (MCF‑7, MDA‑MB‑231, BT‑20, AU‑565) are breast cancer lines and MCF‑10 A is non‑malignant 
breast epithelial cell line. Data were curve fit using the equation provided in methods section. IC50 and Cmax were obtained are presented above. One-way 
ANOVA analysis was performed for statistical analysis to determine the statistical significance of IC50 and Cmax for comparison between unstimulated and 
stimulated groups; significance taken at P<0.05, represented by astericks (*).
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prostratin through inhibition of SIK3. As shown in Fig. 2, pros-
tratin induced a 46% inhibition in the SIK3 mRNA expression 
following stimulation with high salt on MCF-7 cells. Prostratin 
was able to exert this SIK3 inhibition on all four breast cancer 
cells (MCF‑7, MDA‑MB‑231, BT‑20 and AU‑565). Similar 
to evidence from cytotoxicity studies, prostratin exerted 
slightly greater inhibition (54% vs. 46% inhibition, P>0.05, 
statistically non-significant) of SIK3 expression in highly 
invasive MDA‑MB‑231 and BT‑20, over less invasive MCF‑7 
and AU‑565 breast cancer cell lines. Furthermore, along 
with reduced SIK3 expression prostratin also inhibited the 
phosphorylation of SIK3 suggesting an inhibition of SIK3 
mediated downstream signaling.
Prostratin inhibits activation of HDAC4, a SIK3 downstream 
element. Previous studies in our laboratory have demon-
strated that high salt stimulating conditions induce SIK3 
mediated phosphorylation of HDAC4, and siRNA mediated 
knock‑down of SIK3 completely abrogated HDAC4 phos-
phorylation (8). Towards this, as prostratin inhibited SIK3, 
we studied the drug effect on HDAC4 phosphorylation, a 
SIK3 downstream element. As shown in Fig. 3A, prostratin 
inhibited the phosphorylation of HDAC4. Further, ELISA 
based biochemical analysis of HDAC4 activity (Fig. 3B) 
demonstrated that prostratin treated cell lysate obtained 
following treatment with high salt stimulation induced a 
50% inhibition of HDAC4 specific substrate conversion. 
Figure 2. Prostratin inhibits SIK3 expression and phosphorylation in breast cancer cells. (A) Westernblot analysis of SIK3 expression in the total cell lysate 
of MCF7 cells. Immunoprecipitate of SIK3 was probed with phosphor‑serine antibody; U/S, represents unstimulated condition, i.e., cells cultured under basal 
conditions; S, represent cells cultured under high salt stimulating conditions (Δ0.05 M NaCl+0.1 ng/ml IL‑17); Prostratin treatment concentration was 50 µM; 
equi‑volume DMSO was used as vehicle control. (B) SIK3 mRNA transcript expression analysis in MCF‑7 cells performed by quantitative RT‑PCR. (C) SIK3 
mRNA transcript expression analysis in five breast cell lines mentioned above following high salt stimulating conditions with and without 50 µM prostratin. 
Student‑t‑test performed for statistical analysis; significance taken at P<0.05, represented by astericks (*).
Figure 3. Prostratin inhibits HDAC4 phosphorylation in breast cancer cells. (A) Westernblot analysis of HDAC4 phosphorylation in the total cell lysate of MCF7 
cells. (B) ELISA‑based HDAC4 activity analysis performed in MCF‑7 cells under various conditions mentioned above. (C) ELISA‑based HDAC4 activity 
analysis performed in five breast cell lines mentioned above following high salt stimulating conditions with and without 50 µM prostratin.  Student‑t‑test 
performed for statistical analysis; significance taken at P<0.05, represented by astericks (*).
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Taken together, these data indicate that prostratin exerts its 
anti‑tumor effect through inhibition of SIK3/HDAC4 medi-
ated cell proliferation.
Prostratin downregulates CXCR4 in SIK3 dependent manner. 
As our cytotoxicity and SIK3 functional mechanistic data 
suggested that prostratin exerted a slightly higher (but 
statistically insignificant) inhibitory effect on highly inva-
sive MDA‑MB‑231 and BT‑20 cancer cell lines, we tested if 
prostratin could exerted anti-cancer effect through inhibition 
of metastasis. CXCR4 is a well-established metastatic factor 
which is known to promote cancer cell invasion and spreading 
to other organs in patients (24). Importantly, prostratin has 
previously been demonstrated to inhibit CXCR4 expression 
in T-lymphocytes. Therefore, in the present study we tested if 
prostratin inhibited CXCR4 expression in breast cancer cells. 
As shown in Fig. 4A, prostratin treatment inhibited the CXCR4 
expression (from 72.9±7.9% to 31.4±5.1%; P<0.05) following 
high salt stimulation. Prostratin exerted no effect following 
siRNA mediated SIK3 knock down, suggesting prostratin 
inhibits SIK3 induced CXCR4 metastatic factor expression. 
Further, prostratin was able to inhibit CXCR4 in all four breast 
cancer cell lines (Fig. 4C) with no effect on non-malignant 
breast epithelial cell line. These data suggest that prostratin is 
exerts strong anti-cancer effect through potential inhibition of 
metastasis.
Discussion
The natural product prostratin is extensively researched in 
the context of therapy against HIV infection and activation 
of CD4+T lymphocytes. However, there is limited evidence 
to determine the effect of prostratin on cancer cells. Various 
ligand-drug interaction  studies have suggested that prostratin 
exerts its anti‑viral effect through the diacylglycerol (DAG) 
binding domain of protein kinase C (PKC), leading to PKC 
enzymatic activation (11). This logic behind ligand mecha-
nistics of prostratin, a phorbol ester, seems to have to been 
inspired from the understanding of another structurally 
related phorbol ester, phorbol 12‑myristate 13‑acetate (PHA), 
which also stimulates PKC through allosteric activation by 
DAG. However, inspite of structural similarity, while PHA is 
known to promote tumor growth, prostratin is not considered 
to promote tumor growth. Szallasi et al (25) have demon-
strated that prostratin was able to inhibit tumor growth in 
CD1 murine cutaneous tumor models. However, to-date 
limited literature on the exact cytotoxicity doses of pros-
tratin on cancer cell lines. In our current study we report that 
the IC50 of prostratin on four different breast cancer cells 
under basal culture conditions was around 35 µM (Fig. 1) 
however, upon stimulating culture conditions, mimicking 
the real tumor microenvironment, the IC50 was around 
7 µM (Fig. 1), thus suggesting that prostratin might have an 
anticancer effect under in vivo solid tumor environment in 
animal models and humans. Further, it is important to note 
that the IC50 of prostratin on non-malignant breast cells 
(MCF‑10A) under basal culture conditions (which is close to 
basal physiological conditions within human body) is 73 µM 
(Fig. 1). This data strongly suggests that prostratin has a 10 
fold higher therapeutic index and therefore could specifically 
target malignant cells while being safe on normal cells. This 
data could set a stage for future preclinical studies in murine 
tumor models to exactly decipher the anticancer effect and 
therapeutic dose of prostratin.
To date, extensive research with prostratin as an anti-viral 
drug has demonstrated that the drug exerts its effect through 
activation of PKC (11). However, using fibroblast cell lines 
stably transfected with H‑Ras and K‑Ras, Wang et al (26) 
have demonstrated yet another mechanism for prostratin, 
wherein the researchers have demonstrated that prostratin 
inhibits K-Ras/calmodulin interaction and there by inhibiting 
the oncogenic potential of their transfected cell lines. This 
evidence suggests, in addition to PKC activation, prostratin 
could exert its anti-cancer effect through other signaling 
pathways. In the present study as prostratin demonstrated 
higher cytotoxicity when cells were cultured under stimulating 
Figure 4. Prostratin inhibits CXCR4 expression in breast cancer cells. (A) Flow cytometry based analysis for expression of CXCR4 in MCF7 cells. (B) CXCR4 
expression following treatment with SIK3 siRNA and scramble siRNA. ($) represents statistical significance made by comparison between (stimulated+scramble 
siRNA) vs. (stimulated+scramble siRNA+50 µM prostratin) samples. (C) CXCR4 expression analysis performed in five breast cell lines mentioned above 
following high salt stimulating conditions with and without 50 µM prostratin.  Student‑t‑test performed for statistical analysis; significance taken at P<0.05. 
(*) represents statistical significance made by comparison between stimulated and stimulated+prostratin samples.
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conditions (sub-minimal IL-17, 0.1 ng/ml, synergized high 
salt, Δ0.05 M NaCl, culture conditions) commonly found 
in solid tumors. This data suggest that prostratin might act 
through salt‑specific signaling mechanism. Importantly, we 
have recently demonstrated that salt-inducible kinase, SIK3, is 
specifically upregulated and mediated proliferative signaling 
following high salt stimulating conditions. Therefore, we 
tested for the potential effect of prostratin on SIK3 expres-
sion. Previous studies from our laboratory have demonstrated 
that (8), while IL-17 induced both mTORC1 and mTORC2 
pathways, only mTORC2 is a direct upstream signaling 
molecule for SIK3. High salt treatment could directly induce 
SIK3 phosphorylation, which is further enhanced following 
co-treatment with subminimal-IL-17. These studies clearly 
point out that SIK3 is a direct downstream factor for high 
salt synergized inflammatory stress. In our current study as 
we found prostratin could down-regulate the activation of 
SIK3, we wanted to study under treatment conditions wherein 
we had highest stimulation of SIK3 and then quantitatively 
analyze for the prostratin inhibition of SIK3. Therefore, as 
the focus of the current study is SIK3, to have highest stimu-
lation of SIK3 in our current work, we have used high salt 
and sub-minimal IL-17 co-treatment conditions. Our current 
studies demonstrate that prostratin inhibits SIK3 expression 
and phosphorylation (Fig. 2). Also, the phosphorylation and 
activity of histone deacetylase (HDAC4), a direct downstream 
molecule of SIK3 (9), was inhibited by prostratin (Fig. 3). 
Taken together, these data strongly suggest that prostratin 
inhibits SIK3 mediated pro-cancer signaling. However, more 
elaborate studies in the preclinical SIK3 knock-out animal 
models and detailed cell cycle studies would be warranted to 
delineate the effect of prostratin on SIK3 mediated signaling 
in solid tumors.
Prostratin had been shown to elicit anti-HIV effect 
by inducing down-regulation of CD4, C-X-C chemokine 
receptor type 4 (CXCR4), and thereby protecting CD4+T 
cells from HIV-1 entry (12). In acutely infected cells, pros-
tratin is thought to enhance cellular protection possibly due 
to cytostatic effects (27). In the context of cancer CXCR4 
is well-known to induce cancer cell migration and metas-
tasis (24). Elevated membrane expression of CXCR4 is 
observed in several cancers. Further CXCR4 is positively 
correlated with cancer progression and considered a poor 
prognostic biomarker (28). Several factors contribute to the 
upregulation of CXCR4 in malignant cells. Previous studies 
in our laboratory have demonstrated that, under high salt 
stimulating conditions, enhanced SIK3 signaling through 
MMP-9 pathway mediates upregulation of CXCR4 membrane 
expression (8). In our current studies we demonstrate that 
prostratin inhibits CXCR4 expression in breast cancer cell 
lines (Fig. 4). Furthermore, siRNA mediated knockdown of 
SIK3 under high salt stimulating culture conditions did not 
induce expression of CXCR4, thus suggesting that, atleast 
that under our experimental conditions, prostratin mediated 
CXCR4 inhibition is mediated by the direct drug induced 
downregulation of SIK3.
In conclusion, we demonstrated a novel mechanism of 
action for prostratin. SIK3 inhibition could be a novel area 
of drug-target anti-cancer studies. In addition to PKC acti-
vation, prostratin could exert its anti-cancer effect through 
inhibition of SIK3. This data could provide a mechanistic 
basis for further research to study the potential application of 
prostratin as an add-on drug to the anti-cancer chemothera-
peutic regimen.
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